E-ISSN 2602-4837
Ischemia-modified albumin levels in patients with idiopathic sudden sensorineural hearing loss [Tr-ENT]
Tr-ENT. 2019; 29(1): 21-27 | DOI: 10.5606/Tr-ENT.2019.43153

Ischemia-modified albumin levels in patients with idiopathic sudden sensorineural hearing loss

Ahmet Adnan Cırık1, Muhammed Fatih Evcimik2, Gözde Ülfer3, Türkan Yiğitbaşı3, Öztürk Aktaş4
1Department of Otorhinolaryngology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey
2Department of Otorhinolaryngology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey
3Department of Biochemistry, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey
4Department of Otolaryngology, Kocaeli State Hospital, Kocaeli, Turkey

INTRODUCTION: This study aims to investigate whether serum levels of ischemia-modified albumin (IMA) are associated with idiopathic sudden sensorineural hearing loss (ISSNHL).
METHODS: Between December 2015 and June 2017, a total of 17 patients (9 males, 8 females; mean age 49.4±18.0 years; range, 24 to 88 years) with ISSNHL and 24 age- and sex-matched healthy individuals (12 males, 12 females; mean age 44.5±13.3 years; range, 30 to 81 years) as the control group were included in the study. All patients underwent audiometric examination at the time of admission immediately before the beginning of the treatment and weekly after treatment initiation until one month using the Interacoustics AC40 audiometer. Serum IMA levels were evaluated using blood samples from the antecubital vein of both patient and control groups. The samples were centrifuged to separate the serum from the cells. Albumin cobalt binding test was used for IMA measurement.
RESULTS: The mean IMA level was 0.374±0.081 absorbance units (ABSU) (range, 0.205 to 0.536) in the study group at the time of diagnosis, 0.358±0.051 ABSU (range, 0.297 to 0.466) in the post-treatment period, at least four weeks after onset, and 0.358±0.053 ABSU (range, 0.281 to 0.434) in the control group. There was no statistically significant difference between the patient and control groups. The IMA levels of the patients with ISSNHL in the post-treatment period were lower than the onset of illness, although this difference was not statically significant (0.440).
DISCUSSION AND CONCLUSION: Our study results demonstrated that serum IMA levels in the patients with ISSNHL did not differ from the control group.

Keywords: Ischemia-modified albumin, idiopathic sudden sensorineural hearing loss.

Ahmet Adnan Cırık, Muhammed Fatih Evcimik, Gözde Ülfer, Türkan Yiğitbaşı, Öztürk Aktaş. Ischemia-modified albumin levels in patients with idiopathic sudden sensorineural hearing loss. Tr-ENT. 2019; 29(1): 21-27

Corresponding Author: Ahmet Adnan Cırık, Türkiye
LookUs & Online Makale